{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044999","form_type":"8-K","ticker":"NORD","cik":"0001011060","company_name":"Nordicus Partners Corp","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.353910+00:00","generated_at":"2026-05-30T00:45:11.676057+00:00","sec_items":["1.01","2.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Nordicus acquires remaining ~5% of Orocidin, making it wholly owned subsidiary","bullets":["Acquired 29,663 Orocidin shares (5.34% of outstanding) for 200,000 restricted common shares.","Transaction closed November 12, 2024; Orocidin now 100% owned by Nordicus.","Orocidin is a clinical-stage biopharma developing periodontitis therapies.","Follows Nordicus' May 2024 purchase of 95% of Orocidin."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044999","json":"https://secwatch.observer/filing/0001493152-24-044999.json","markdown":"https://secwatch.observer/filing/0001493152-24-044999.md","text":"https://secwatch.observer/filing/0001493152-24-044999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224044999/0001493152-24-044999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224044999/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:45:11.676057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}